SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]
- Market Cap ₹ 1,509 Cr.
- Current Price ₹ 178
- High / Low ₹ 198 / 56.8
- Stock P/E 36.3
- Book Value ₹ 60.7
- Dividend Yield 0.17 %
- ROCE 3.66 %
- ROE 0.84 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 23.4%
Cons
- Stock is trading at 2.94 times its book value
- The company has delivered a poor sales growth of 2.44% over past five years.
- Company has a low return on equity of 9.84% over last 3 years.
- Debtor days have increased from 68.8 to 104 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
217 | 248 | 518 | 587 | 611 | 438 | 463 | 465 | 412 | 563 | 520 | 522 | 613 | |
179 | 284 | 461 | 500 | 522 | 363 | 369 | 375 | 332 | 442 | 405 | 467 | 506 | |
Operating Profit | 38 | -36 | 57 | 86 | 89 | 75 | 93 | 90 | 80 | 121 | 115 | 55 | 107 |
OPM % | 17% | -14% | 11% | 15% | 15% | 17% | 20% | 19% | 19% | 22% | 22% | 10% | 17% |
1 | 104 | 2 | 16 | 4 | 1 | 2 | 3 | 5 | 3 | 5 | 5 | 4 | |
Interest | 24 | 24 | 14 | 18 | 17 | 16 | 15 | 12 | 12 | 11 | 19 | 22 | 24 |
Depreciation | 13 | 14 | 13 | 17 | 19 | 19 | 20 | 19 | 22 | 22 | 32 | 32 | 32 |
Profit before tax | 1 | 30 | 32 | 67 | 56 | 42 | 60 | 62 | 51 | 91 | 69 | 6 | 55 |
Tax % | 20% | 15% | 36% | 48% | 26% | 14% | 33% | 34% | 36% | 33% | 1% | 26% | |
1 | 25 | 20 | 35 | 42 | 36 | 40 | 41 | 33 | 61 | 68 | 4 | 42 | |
EPS in Rs | 0.11 | 2.53 | 2.40 | 4.15 | 4.92 | 4.20 | 4.78 | 4.89 | 3.86 | 7.20 | 8.03 | 0.48 | 4.91 |
Dividend Payout % | 0% | 8% | 8% | 5% | 4% | 5% | 5% | 5% | 6% | 4% | 4% | 62% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 2% |
3 Years: | 8% |
TTM: | 41% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | -37% |
3 Years: | -50% |
TTM: | 720% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 23% |
3 Years: | 13% |
1 Year: | 215% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 10% |
3 Years: | 10% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | 211 | 234 | 213 | 246 | 286 | 254 | 293 | 331 | 359 | 420 | 485 | 487 | 505 |
207 | 149 | 167 | 167 | 204 | 149 | 146 | 144 | 157 | 255 | 263 | 254 | 277 | |
64 | 79 | 120 | 119 | 158 | 89 | 72 | 93 | 103 | 147 | 126 | 165 | 221 | |
Total Liabilities | 492 | 471 | 509 | 540 | 656 | 501 | 519 | 577 | 627 | 830 | 883 | 914 | 1,012 |
225 | 147 | 247 | 277 | 370 | 290 | 279 | 281 | 280 | 457 | 438 | 412 | 407 | |
CWIP | 49 | 96 | 39 | 29 | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 43 |
Investments | 1 | 26 | 6 | 13 | 21 | 37 | 45 | 45 | 45 | 45 | 45 | 45 | 45 |
217 | 203 | 217 | 221 | 252 | 166 | 187 | 232 | 259 | 321 | 389 | 424 | 517 | |
Total Assets | 492 | 471 | 509 | 540 | 656 | 501 | 519 | 577 | 627 | 830 | 883 | 914 | 1,012 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
20 | -33 | 65 | 59 | 61 | 73 | 32 | 50 | 40 | 90 | 45 | 22 | |
25 | 99 | -37 | -55 | -79 | -39 | -17 | -35 | -43 | -152 | -27 | -30 | |
8 | -59 | -30 | -10 | 27 | -33 | -15 | -13 | -2 | 92 | -12 | -32 | |
Net Cash Flow | 52 | 7 | -2 | -6 | 9 | 1 | 0 | 2 | -5 | 31 | 6 | -39 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 65 | 52 | 39 | 37 | 36 | 18 | 19 | 20 | 43 | 68 | 34 | 104 |
Inventory Days | 421 | 192 | 90 | 81 | 106 | 114 | 135 | 170 | 191 | 148 | 333 | 243 |
Days Payable | 108 | 83 | 59 | 58 | 79 | 82 | 49 | 59 | 66 | 70 | 97 | 123 |
Cash Conversion Cycle | 377 | 161 | 70 | 61 | 63 | 50 | 105 | 131 | 169 | 146 | 270 | 224 |
Working Capital Days | 213 | 126 | 65 | 62 | 63 | 48 | 73 | 95 | 111 | 115 | 172 | 196 |
ROCE % | 6% | -12% | 12% | 21% | 16% | 13% | 18% | 16% | 13% | 17% | 12% | 4% |
Documents
Announcements
- Closure of Trading Window 3m
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 26 Mar
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 26 Mar
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 21 Mar
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 21 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Oct 2021TranscriptNotesPPT
Product Portfolio
The company offers various pharmaceutical products under various therapeutic categories such as Anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-diabetic, anti-retroviral and others.[1] Antiretroviral and anti-ulcer are the key therapeutic segments contributing ~60% of total sales of the company.[2]